Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Axelsson

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Cardiovascular Endocrinology|April 11, 2017
The inflammatory biomarker YKL-40 decreases stepwise after exercise stress testNaja Dam Mygind, Anna Axelsson, Martin H Ruwald, et al.
Heart (British Cardiac Society)|December 15, 2015
Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
Circulation|December 1, 2012
Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testingMorten K Jensen, Ole Havndrup, Michael Christiansen, et al.
International Journal of Cardiology|May 1, 2013
Exercise-induced changes in left ventricular filling pressure after myocardial infarction assessed with simultaneous right heart catheterization and Doppler echocardiographyMads J Andersen, Mads Ersbøll, Finn Gustafsson, et al.
Circulation|August 16, 2015
Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy: A Nationwide Family Study in a Cohort of 3.9 Million PersonsMattis F Ranthe, Lisbeth Carstensen, Nina Øyen, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 26, 2014
Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathyAnna Axelsson, Kristina Weibring, Ole Havndrup, et al.
American Heart Journal|November 18, 2023
Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trialsTino Severinsen, Jens Jakob Thune, Helga Lillian Gudmundsdottir, et al.
The Lancet. Diabetes & Endocrinology|December 24, 2014
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
International Journal of Cardiology|November 20, 2015
Left ventricular volume predicts exercise capacity in hypertrophic cardiomyopathyAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
Neonatology|July 20, 2022
The Impact of Maternal Age on the Neonatal ElectrocardiogramMaria Munk Pærregaard, Joachim Hartmann, Ottilia Vøgg, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Cardiovascular Endocrinology|April 11, 2017
The inflammatory biomarker YKL-40 decreases stepwise after exercise stress testNaja Dam Mygind, Anna Axelsson, Martin H Ruwald, et al.
Heart (British Cardiac Society)|December 15, 2015
Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
Circulation|December 1, 2012
Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testingMorten K Jensen, Ole Havndrup, Michael Christiansen, et al.
International Journal of Cardiology|May 1, 2013
Exercise-induced changes in left ventricular filling pressure after myocardial infarction assessed with simultaneous right heart catheterization and Doppler echocardiographyMads J Andersen, Mads Ersbøll, Finn Gustafsson, et al.
Circulation|August 16, 2015
Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy: A Nationwide Family Study in a Cohort of 3.9 Million PersonsMattis F Ranthe, Lisbeth Carstensen, Nina Øyen, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|March 26, 2014
Atrioventricular conduction after alcohol septal ablation for obstructive hypertrophic cardiomyopathyAnna Axelsson, Kristina Weibring, Ole Havndrup, et al.
American Heart Journal|November 18, 2023
Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trialsTino Severinsen, Jens Jakob Thune, Helga Lillian Gudmundsdottir, et al.
The Lancet. Diabetes & Endocrinology|December 24, 2014
Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trialAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
International Journal of Cardiology|November 20, 2015
Left ventricular volume predicts exercise capacity in hypertrophic cardiomyopathyAnna Axelsson, Kasper Iversen, Niels Vejlstrup, et al.
Neonatology|July 20, 2022
The Impact of Maternal Age on the Neonatal ElectrocardiogramMaria Munk Pærregaard, Joachim Hartmann, Ottilia Vøgg, et al.
Pageof 10